Literature DB >> 20838332

Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients.

Yahya Shehabi1, Richard R Riker, Paula M Bokesch, Wayne Wisemandle, Ayumi Shintani, E Wesley Ely.   

Abstract

OBJECTIVES: To determine the relationship between the number of delirium days experienced by intensive care patients and mortality, ventilation time, and intensive care unit stay.
DESIGN: Prospective cohort analysis.
SETTING: Patients from 68 intensive care units in five countries. PATIENTS: Three hundred fifty-four medical and surgical intensive care patients enrolled in the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared with Midazolam) trial received a sedative study drug and completed at least one delirium assessment.
INTERVENTIONS: Sedative drug interruption and/or titration to maintain light sedation with daily arousal and delirium assessments up to 30 days of mechanical ventilation.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was all-cause 30-day mortality. Multivariable analysis using Cox regression incorporating delirium duration as a time-dependent variable and adjusting for eight relevant baseline covariates was conducted to quantify the relationship between number of delirium days and the three main outcomes. Overall, delirium was diagnosed in 228 of 354 patients (64.4%). Mortality was significantly lower in patients without delirium compared to those with delirium (15 of 126 [11.9%] vs. 69 of 228 [30.3%]; p<.001). Similarly, the median time to extubation and intensive care unit discharge were significantly shorter among nondelirious patients (3.6 vs. 10.7 days [p<.001] and 4 vs. 16 days [p<.001], respectively). In multivariable analysis, the duration of delirium exhibited a nonlinear relationship with mortality (p=.02), with the strongest association observed in the early days of delirium. In comparison to 0 days of delirium, an independent dose-response increase in mortality was observed, which increased from 1 day of delirium (hazard ratio, 1.70; 95% confidence interval, 1.27-2.29; p<.001), 2 days of delirium (hazard ratio, 2.69; confidence interval, 1.58-4.57; p<.001), and ≥3 days of delirium (hazard ratio, 3.37; confidence interval, 1.92-7.23; p<.001). Similar independent relationships were observed between delirium duration and ventilation time and intensive care length of stay.
CONCLUSIONS: In ventilated and lightly sedated intensive care unit patients, the duration of delirium was the strongest independent predictor of death, ventilation time, and intensive care unit stay after adjusting for relevant covariates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838332     DOI: 10.1097/CCM.0b013e3181f85759

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  122 in total

Review 1.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

3.  Effect of delirium motoric subtypes on administrative documentation of delirium in the surgical intensive care unit.

Authors:  Lan N Bui; Vy P Pham; Beverly A Shirkey; Joshua T Swan
Journal:  J Clin Monit Comput       Date:  2016-04-23       Impact factor: 2.502

4.  Agitation, Delirium, and Cognitive Outcomes in Intracerebral Hemorrhage.

Authors:  Lisa J Rosenthal; Brandon A Francis; Jennifer L Beaumont; David Cella; Michael D Berman; Matthew B Maas; Eric M Liotta; Robert Askew; Andrew M Naidech
Journal:  Psychosomatics       Date:  2016-08-05       Impact factor: 2.386

5.  Acute brain failure in severe sepsis: a prospective study in the medical intensive care unit utilizing continuous EEG monitoring.

Authors:  Emily J Gilmore; Nicolas Gaspard; Huimahn A Choi; Emily Cohen; Kristin M Burkart; David H Chong; Jan Claassen; Lawrence J Hirsch
Journal:  Intensive Care Med       Date:  2015-03-13       Impact factor: 17.440

6.  Statins and delirium during critical illness: a multicenter, prospective cohort study.

Authors:  Alessandro Morandi; Christopher G Hughes; Jennifer L Thompson; Pratik P Pandharipande; Ayumi K Shintani; Eduard E Vasilevskis; Jin H Han; James C Jackson; Daniel T Laskowitz; Gordon R Bernard; E Wesley Ely; Timothy D Girard
Journal:  Crit Care Med       Date:  2014-08       Impact factor: 7.598

Review 7.  Randomized ICU trials do not demonstrate an association between interventions that reduce delirium duration and short-term mortality: a systematic review and meta-analysis.

Authors:  Nada S Al-Qadheeb; Ethan M Balk; Gilles L Fraser; Yoanna Skrobik; Richard R Riker; John P Kress; Shawn Whitehead; John W Devlin
Journal:  Crit Care Med       Date:  2014-06       Impact factor: 7.598

8.  Deficits in Self-Reported Initiation Are AssociatedWith Subsequent Disability in ICU Survivors.

Authors:  Jo Ellen Wilson; Maria C Duggan; Rameela Chandrasekhar; Nathan E Brummel; Robert S Dittus; Eugene Wesley Ely; Mayur B Patel; James C Jackson
Journal:  Psychosomatics       Date:  2018-09-29       Impact factor: 2.386

9.  Delirium Monitoring in Neurocritically Ill Patients: A Systematic Review.

Authors:  Mayur B Patel; Josef Bednarik; Patricia Lee; Yahya Shehabi; Jorge I Salluh; Arjen J Slooter; Kate E Klein; Yoanna Skrobik; Alessandro Morandi; Peter E Spronk; Andrew M Naidech; Brenda T Pun; Fernando A Bozza; Annachiara Marra; Sayona John; Pratik P Pandharipande; E Wesley Ely
Journal:  Crit Care Med       Date:  2018-11       Impact factor: 7.598

10.  Associations of markers of inflammation and coagulation with delirium during critical illness.

Authors:  Timothy D Girard; Lorraine B Ware; Gordon R Bernard; Pratik P Pandharipande; Jennifer L Thompson; Ayumi K Shintani; James C Jackson; Robert S Dittus; E Wesley Ely
Journal:  Intensive Care Med       Date:  2012-08-18       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.